Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Change in Account Payables (2020 - 2025)

Historic Change in Account Payables for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Q3 2025 value amounting to -$9.3 million.

  • Arcutis Biotherapeutics' Change in Account Payables fell 24276.05% to -$9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.5 million, marking a year-over-year decrease of 84758.98%. This contributed to the annual value of $2.2 million for FY2024, which is 2928.3% down from last year.
  • Per Arcutis Biotherapeutics' latest filing, its Change in Account Payables stood at -$9.3 million for Q3 2025, which was down 24276.05% from $554000.0 recorded in Q2 2025.
  • Arcutis Biotherapeutics' 5-year Change in Account Payables high stood at $6.5 million for Q3 2024, and its period low was -$9.3 million during Q3 2025.
  • Its 5-year average for Change in Account Payables is -$64947.4, with a median of $217000.0 in 2022.
  • In the last 5 years, Arcutis Biotherapeutics' Change in Account Payables tumbled by 193133.64% in 2023 and then surged by 26371.41% in 2024.
  • Arcutis Biotherapeutics' Change in Account Payables (Quarter) stood at $2.4 million in 2021, then tumbled by 92.39% to $182000.0 in 2022, then crashed by 755.49% to -$1.2 million in 2023, then surged by 91.2% to -$105000.0 in 2024, then tumbled by 8745.71% to -$9.3 million in 2025.
  • Its last three reported values are -$9.3 million in Q3 2025, $554000.0 for Q2 2025, and $309000.0 during Q1 2025.